| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |